These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

Bluebird bio went public in 2013, raising approximately $116m through its IPO. The company has developed three US Food and Drug Administration (FDA)-approved gene therapy products, including Zynteglo ...

Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital ...

Somerville gene therapy company bluebird bio, once among the highest-profile biotechs in the Boston area, has agreed to be ...

The agreement, which also includes a team of biotech executives, will see Bluebird Bio’s stockholders receive $3.00 per share ...

(NASDAQ:BLUE) lost ~37% in the premarket on Friday after the gene therapy developer announced its plans to become a privately held biotech as part of an M&A agreement with private equity firms Carlyle ...

Inc. ("bluebird") today announced that it has entered into a definitive agreement to be acquired by funds managed by global investment firms Carlyle and SK Capital Partners, LP ("SK Capital") in ...

For many Filipinos, receiving a medical diagnosis is supposed to provide clarity. But for those with rare diseases, it often ...

Following the non-adoption of key financial delegations at the Combined General Meeting held on February 11, 2025, the Company is facing an uncertain and adverse situation regarding the continuation ...

Government of India has provided tax relief on life-saving drugs and medicines used for rare diseases. As per the Ministry of Finance’s response in Rajya Sabha on February 11, 2025, basic customs duty ...

Poxel announces results of its Combined General Meeting with approved resolutions on revised remuneration policy for corporate officers. Details available on company's website ...